Literature DB >> 11035467

Horizontal transmission of HBV infection among students in Turkey.

H Değertekin1, A Tuzcu, K Yalçin.   

Abstract

In this study, the HBsAg carrier state and the role of horizontal transmission were investigated among primary and high school students in southeastern Anatolia where HBsAg seropositivity is remarkably high. In total, 350 students from primary school first grade, 350 students from fifth grade, 400 students from high school eleventh grade and 400 healthy adults as a control group were studied. In all cases HBsAg and anti-HBs were screened by ELISA. HBsAg positivity was 2.4% in first grade, 6.1% in fifth and 6.7% in eleventh grade students. Anti-HBs positivity was 14% in first grade, 20% in fifth and 21% in eleventh grade students. HBsAg positivity was 9% and anti-HBs, 49% in the control group. There is a significant difference between first and fifth grade students for HBsAg positivity (2.1% vs 6.1% and P<0.05). This difference decreased during the high school years (6.2% and P>0.05). There is also a similar statistically significant difference for anti-HBs positivity during the primary school years (14% vs 20%, P<0.05). These findings show that the risk of horizontal transmission of HBV is especially important during elementary school years between the ages of 7 and 11 y. All infants or at least elementary school first grade students in Turkey should have HBV vaccinations.

Entities:  

Keywords:  Antibodies; Antigens; Asia; Biology; Case Control Studies; Developing Countries; Diseases; Education; Hepatitis; Immunity; Immunologic Factors; Mediterranean Countries; Physiology; Primary Schools; Research Methodology; Research Report; Schools; Secondary Schools; Students; Studies; Turkey; Viral Diseases; Western Asia

Mesh:

Substances:

Year:  2000        PMID: 11035467     DOI: 10.1038/sj.ph.1900684

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   2.427


  7 in total

1.  Relationship between age and prevalence of hepatitis B infection in first-year university students in Hong Kong.

Authors:  S S H Suen; T T Lao; O K Chan; T K Lau; T Y Leung; P K S Chan
Journal:  Infection       Date:  2012-12-12       Impact factor: 3.553

Review 2.  Molecular mechanisms underlying occult hepatitis B virus infection.

Authors:  Jasmine Samal; Manish Kandpal; Perumal Vivekanandan
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

3.  Seroprevalence of Hepatitis B and C among Children in Endemic Areas of Turkey.

Authors:  Murat Kangin; Mine Turhanoglu; Serda Gulsun; Bahri Cakabay
Journal:  Hepat Mon       Date:  2010-03-01       Impact factor: 0.660

Review 4.  Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review.

Authors:  Mehlika Toy; Fatih Oguz Önder; Tanja Wörmann; A Mithat Bozdayi; Solko W Schalm; Gerard J Borsboom; Joost van Rosmalen; Jan Hendrik Richardus; Cihan Yurdaydin
Journal:  BMC Infect Dis       Date:  2011-12-12       Impact factor: 3.090

5.  Hepatitis B virus prevalence and risk factors in hard-to-reach Turkish population living in Belgium: A protocol for screening.

Authors:  Özgür M Koc; Niel Hens; Rob Bielen; Pierre Van Damme; Geert Robaeys
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

6.  Hepatitis B virus transmission in pre-adolescent schoolchildren in four multi-ethnic areas of England.

Authors:  M A Balogun; J V Parry; K Mutton; C Okolo; L Benons; H Baxendale; T Hardiman; E H Boxall; J Sira; M Brown; S Barnett; U Gungabissoon; A Williams; D A Kelly; S Vijeratnam; S Ijaz; B Taylor; C G Teo; M E Ramsay
Journal:  Epidemiol Infect       Date:  2012-07-31       Impact factor: 4.434

Review 7.  Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.

Authors:  Susan J M Hahné; Irene K Veldhuijzen; Lucas Wiessing; Tek-Ang Lim; Mika Salminen; Marita van de Laar
Journal:  BMC Infect Dis       Date:  2013-04-18       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.